Allergic rhinitis is the most prevalent chronic allergic disease in children. Although it is not life-threatening, it can ha ve a Significantly detrimental ef fec t on a child's quality oflife, and it may exacerbate a number ofcommon comorb idities, including asthma and sinusitis. The Allergic Rhinitis and its Imp act on Asthma guidelines, an evidence-based algorithmfor the treatment ofallergic rhinitis, advocate the use ofantihistamines/or the treatment ofthe broad spectrum of the disease. However; first-generation antihistamin es are assoc iated with a number ofadverse events, including central nervous system impairm ent and anticholinergic and cardio vascular effects. Moreover; these agents have not been rigorously tested in thep ediatric population. Nevertheless,first-generation antihistamines remain the most frequently pres cribed agents in this class ofdrugs . This is despite the/act that the second-generation antihistamines are largely F ee of the undesirab le.side effects associated with their predecessors and the fact that they have been shown to be effe ctive in relieving allergic rhinitis symp toms in children in a number oflarge-scale clinical trials. Therefore, when sele cting an antihistamine for a child, it would be prudent to consider thefu ll range ofantihistamines and to base the selection ofa particular drug on its effi cacy, onset and duration 0/action, and safety profile.
palate, throat, and/or ears. Allergic rhinitis can be classified as either intermittent or persistent; persistent allergic rhinitis is subc lassifie d as either seasonal or perennial, depending on the duration and frequency of symptoms . Alle rgic rhinit is is most common in chi ldren; the mea n age of patients at its onset is approx imately 10 years and its incidence peaks between the ages of 13 and 19 yea rs.i-'
Although allergic rhinit is is not an ac ute disease, it can have an important negat ive impac t on the quality oflife in chi ldren , impairing their learni ng perfo rmance.P red ucing the ir ab ility to concentrate.?? and ca using dfsturbed sleep patterns.' Moreover, allergic rhinitis may also be assoc iated with the development of other allergic diseases-the soca lled allergic march . Left untreated, allergic rhinitis may exacerbate asth ma, another prevalent childhood chronic disease with a high burden of morbidity.S A range of other disorders has also been linked to ped iatric allergic rhinitis, including sinusitis, sleep apnea, nasa l po lyposis, nasa l co llapse , heari ng impair ment, abnor ma l craniofacial development , and impaired cogn itive functioning."
Give n the hig h prevalence ofallergic rhinitis in children, its negative impact on quality of life, and its potential to exacerbate or lead to other disorders, there is little doubt that the disease warra nts effective treatment and management. In this article , the aut hor reviews the efficacy, the onset and duration of action , and the safe ty of currently available treatments .
Overview of treatment options
As is the case with many other allergic disorders, first-line treatment for allerg ic rhinitis is allergen avoi dance. The ease with which this can be accomplishe d depends on the type of allergen invo lved . Indoors, a range of meas ures can be taken to reduce the allergen load. Aggressive cleaning-particularly of carpets, curtai ns, and bedding-can be effective. However, the efficacy of nonallergenic bedcovering products is still quest ionab le; whereas some studies have shown that they are associate d with a reduction in allergic rhinitis symptoms," others have found them to be of litt le benefit when used alone." Ubiquitous aeroallergens such as pollen are harder to avoi d, and patients who are sensitive to them are therefore more likely to require medication to relieve their symptoms .
The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines were deve loped by the World Health Organization to establish an evidence-based protocol for the treatment of allergic rhinitis ." These guidelines provide a usefu l point of reference for physicians who treat both adults and children with allergic rhinitis. They contain a stepwise approach to treatment to maximi ze its beneficial effects while minimizing its adverse effects . In view of children's developmental vulnerability, the guidelines include a recommendation that physicians pay special attention to the risk/benefit ratio of any therapeutic intervention in this population.
The AR IA guidelines also include a review of the therapeutic agents that are indicated for the treatment of allergic rhinitis, including oral and intranasal antihistamines, intranasal glucocorticosteroids, local chromones, oral and intranasal decongestants, intranasal anticholinergics , and antileukotrienes."The suitability and availability of these agents in chi ldren vary. For example, intranasal glucocorticosteroids, with their global effects on the inflammatory response, are indicated only for moderateto-severe or persistent allerg ic rhinitis. The guide lines' authors express some concern about the use of intranasal glucocorticosteroids in children, and they stress the need for monitoring these children. Very few intranasal glucocorticosteroid therapies have been approved for children, and none is available for chi ldren younger than 3 years of age. In contrast, antihistamines are indicated for the broad spectrum of allergic rhinit is severity, and oral formulations of this drug class remain the mainstay of treatment in children.
Phenbenzamine, the first available antihistamine, was developed in the 1940s. It was succeeded by a number of similar agents, including chlorpheniramine, brompheniramine, diphenhydramine, promethazine, and hydroxyzine. These older, first-generation antihistamines were associated with a range of adverse effects , including sedation, dry mucous membranes, and tachycard ia. The second-generation agents-fexofenadine, loratadine, cetirizine, and azelastine-were developed in recent years to reduce these side effects. A number offirst-and second-generation oral and inhaled antihistamines have been approved for use in children and are avai lable either as over-the-counter or prescription-only drugs (table ) .
Antihistamines are antagonists to the H I histamine receptor, and they reduce inflammation by blocking the histamine-driven inflammatory cascade. However, although all antihistamines mediate their therapeutic effects via the same primary mechanism, each agent has different properties, both positive and negati ve. Therefore, product selection should be tailored to the needs ofeach patient. A . range ofcriteria should be borne in mind when making this selection, including efficacy, onset and duration of action , and safety profile beca use there are important differences among the antihistamines in each of these areas.
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Efficacy
The best evidence ofthe benefits ofantihistamine use in the pediatric population is provided by well-designed clinical trials . Such data are generally not available for the first-generation agents because they were introduced at a time when study requirements were less rigid than they are today. The most recent data on the first-generation agents derive from their use as active controls in studies ofsecond-generation agents. This means that although diphenhydramine is the most widely used antihistamine in the United States," its exact benefits in terms of symptom reduction are unclear, particularly in the ped iatric population. The paucity ofdata from well-designed studies coupled with concerns over tolerability led a recent consensus group to recommend that the use of first-generation antihistamines should be limited in all patients with allergic rhinitis."
The efficacy and safety of some second-generation antihist amines in children have been assessed in a number of well-designed clinical trials. Four of these agents are currently available for use in children in the U.S. : fexofenadine is indicated for use in children aged 6 years and older, loratadine for children 2 years or older, cetirizine for children 6 months and older, and azelastine for children 5 years and older. (The secondary metabolite of loratadine, desloratadine, is currently approved only for patients aged 12 years and older.) However, there have been no head-tohead trials among the second-generation agents in children, so direct comparisons are not possible.
Fexofenadine. In 2000, fexofenadine was approved in the U.S. for the treatment of seasonal allergic rhinitis in children aged 6 to II years . This antihistamine was shown to alleviate symptoms in a placebo-controlled, double-blind study of 935 children aged 6 to II years in 15 countries." The primary endpoint of this study was the change from basel ine in the mean total symptom score; these symptoms included sneezing; rhinorrhea; itchy nose , mouth, throat, and/or ears; and itchy, watery, and/or red eyes. Nasal congestion was assessed separately.At study 's end, children who had taken fexofenadine 30 mg twice daily had a significantly lower mean tota l symptom score than did those in the placebo control group (p :::: 0.000 1). The mean change from baseline for the fexofenadinetreated group was 1.94 compared with 1.21 for the placebo group. Moreover, secondary endpoint analyses revealed that fexofenadine was significantly more effective than placebo in reducing individual symptom scores, including those for nasa l congestion (p :::: 0.05 for each symptom). The data also suggest that fexofenadine is rapidly effective, as improvement in both individual and total symptom scores were observed on the first day oftreatment and were maintained throughout the entire 14-day trial.
Loratadine. Loratadine is available over the counter for the treatment of seasonal and perennial allergic rhinitis as a tablet (10 mg loratadine in the pediatric popu lation have included only relatively small numbers ofpatients. The initial efficacy data on loratadine for seasonal allergic rhinitis were obtained during a l4-day trial of 40 children aged 3 to 6 years." A total of2 I patients received loratadine syrup at O. I I to 0.24 mglkg ideal body weight once daily, and 19 children received first-generation dexch lorphen iramine syrup atO.l 0 to 0.23 mg/kg every 8 hours . The efficacy data showed that loratadine was ju st as effective as dexc hlorpheniramine in terms of alleviating nasa l and ocular symp toms.
A randomized, doub le-blind, parallel -group study of96 children aged 3 to 6 years with seasonal allergic rhinitis showed that the therapeutic response at the study's endpoint was rated by physicians as good or excellent in 82% of children who took loratadine syrup at 5 or 10 mg once daily for 14 days, compared with only 60% of those who took terfenadine suspension at 15 mg twice daily for 14 days ." According to physicians' ratings, treatment outcomes were simi lar across groups , except at day 14 when the response was significan tly better in the loratadine group (p :s 0.02) .
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Nasal and nonnasal symptom severities were also rated by physicians on a 4-point scale at baseline and on treatment days 3,7, and 14.Mean nasal and nonnasal scores decreased significantly from baseline in both groups at each test point (p < 0.05), with greater nonnasal symptom improvement found in the loratadine group at day 14 (p = 0.05).
Cetirizine. Cetirizine is approved for the treatment of seasonal allergic rhinitis in children aged 2 years and older and for perennia l allergic rhinitis in those aged 6 months and older. Several tria ls have eval uated cetirizine in children, but they all differed in sca le, contro ls, and primary endpoints.v'? Overall, these studies have shown that cetirizine is an effective treatment for allergic rhinitis in children, but there is some variation in outcomes among these trials.
The largest of these trials was a randomized, doubleblind , placebo-controlled study of cetirizine syrup at 5 and 10 mg once daily in the treatment of seasonal allergic rhinitis in 209 children aged 6 to 1I years." At 4 weeks, cetir izine 10 mg was significa ntly better than placebo in lowering total symptom scores (p < 0.05); there was no significant difference between placebo and the 5-mg dose of cetirizine.
Another study showed that cetirizine at 5 and 10 mg was as effective as chlorpheniramine in reducing total symptom scores in 188 children aged 6 to II years with allergic rhinitis.I? Similar studies have shown that cetirizine is effective in children and in infants as young as 6 months of age. IS . 19 Azelastine. Azelastine is approved for the treatment of seasona l allergic rhinitis in children aged 5 years and older.Unlike the other second-generation agents discussed here, azelastine is not an oral preparation; it is delivered as a nasal spray. The .efficacy of azelastine in pediatric allergic rhinitis has not been clinically assessed. Instead, the efficacy of a 1 2 5 -~l g dose has been extrapolated from adult studies. This dose was found to be safe and well tolerated in an initial series of controlled safety studies in 176 children aged 5 to 12 years who were treated over 6 weeks." The efficacy of this dose has not yet been established in children.
Onset and duration of action
Given the relatively small variations in efficacy among the second-generation antihistamines, other factors-including the onset and duration of action and the incidence of side effects-are important considerations in the selection of treatment.
Antihistamines are often used intermittently, and as such theyshouldhave a rapid onsetofaction, which can minimize disruption of the patient's daily life. Histamine-induced wheal-and-flare skin reactivity testing is the gold standard for measuring the onset and duration ofperipheral HI receptor blockade by an antihistamine." :" This assay has been used widely in adult studies to assess the newer-generation antihistamines. Forexample, Simons and Simons used this technique to compare loratadine 10 mg and fexofenadine 120mg." They found that although both medications were effective in suppressing histamine-induced whealand flare for 24 hours, fexofenadine had a significantly faster onset of action. In a similar comparative study, Day et al found that the onset of action of cetirizine 10 mg occurred at I hour, versus 3 hours with loratadine 10 mg."
However, comparable pharmacologic data in children are limited, as studies ofthis nature in special populations have only recently been conducted. In one of the first of these studies, Simons et al compared the pharmacology of single doses of fexofenadine 30 mg and cetirizine 10 mg in children with allergies." They enrolled 15 children (mean age: 8.8 ± 0.5 yr) in a randomized, double-blind, crossover, single-dose study. The authors found that while both cetirizine and fexofenadine significantly suppressed the wheal-and-flare reaction over the 24-hour test period, cetirizine demonstrated greater HI activity. However, it should be noted that the single test dose of fexofenadine 16 6 was 30 mg, which is not the currently recommended daily dosage for children aged 6 to II years (the recommended dosage is30 mg twice daily). Furthermore, cetirizine 10 mg is the larger of two available doses indicated for children and is equivalent to the adult dose. Children aged 6 to 24 months and 2 to 5 years can be prescribed 2.5 to 5 mg of cetirizine; the 2.5-mg dose is administered as one-half a teaspoon of syrup.
Although it is clear that this subject merits further research, it is important to recognize that wheal-and-flare testing is not a direct substitute for clinical efficacy trials. Further clinical pharmacologic trials should be conducted in this population.
Safety profile
First-generation antihistamines have long been associated with a range of adverse events, including impairment of the central nervous system (CNS) and anticholinergic and cardiovascular effects. Many of these adverse effects arise as a result of the first-generation agents' lower degree of specificity for the HI receptor and their propensity to cross the blood-brain barrier. Consequences are particularlyserious in cases of overcompliance or overdose. More than 14,000 accidental exposures to first-generatio n antihistamines in children younger than 6 years ofage occur every year in the U.S., and these exposures have resulted in several fatalities and severe toxic reactions." For example, accidental ingestion of diphenhydramine caused multiple seizures and the eventual death of a 15-month-old boy.'?
Second-generation antihistamines with HI receptor specificity are genera lly not associated with such adverse effects. Fewcases of overdose have been reported, butwhen they have occurred, outcomes have been generallysatisfactory. For example, an 18-month-old boy who ingested 180 mg of cetirizine remained asymptomatic and exhibited no electrocardiographic (ECG) abnormalities."
Learning impairment. Studies have shown that poorly controlled allergic rhinitiscan have a significant impact on a child's development and social integration, particularly with respectto leamingp erformance.t'It has beenestimated that more than 1.5 million school days are lost each year in the U.S. as a direct result of allergic rhinitis.'
Unfortunately, treatment of allergic rhinitis with firstgeneration antihistamines appears to have exacerbated learning impairment. Vuurman et al compared the effects ofantihistamines on children's learning ability and found that diphenhydramine caused significantly more impairment than did loratadine.' Ina subsequent study, these same researchers found that diphenhydramine compounded the learning disability associated with allergic rhinitis."
In contrast, second-generation antihistamines that cause significantly fewer adverse CNS effects may be less likely to have a negat ive impact on academ ic performance, particularly in children who require medication for prolonged periods of time. For example, in a large, double-blindstudy ENT-Ear, Nose & Throat Joumal s March 2005 of574 children, Reillyetal found that fexofenadine therapy was associated with reduced absenteeism and improved classroom perform ance ."
However, Bender et al reported that the intermittent use of antihistamines by patients with mild symptoms is unlikely to have any lasting negative effect on learning performance."
Sedation Sedation is the most common ad verse effect associated with the first-generation antihistamines.
It occurs secondary to the drugs ' penetration of the blood-brain barrier. Indeed, a number of first-generation ant ihistamines-diphenhydramine, promethazine, and hydroxyzine-have been used to sedate children prior to electroencephalography (EEG ), and they are still recommended by some physicians for sed ation , pain relief, and as an antinaus ea medication for infants prior to surgery .' The authors of the ARIA guid elin es recommend avoiding the "global impairment ofpsychomotor performance" observed with the older-generation antihistamines."
Data from clinical trials in adults have established that some second-generation antihistamines are nonsedating . 35 .36 Similar observations have been made in the pediatric population.P:" For example, during a safety study of fexofenadine in 875 children, the incid ence ofsomnolence was comparable in those children who received the drug and in those who received placebo ." Similarly, Melt zer et al recently conducted a pooled analysis of three 2-week placebo-controlled trials of fexofenadine (at 15, 30, and 60 mg twice daily) in children aged 6 to I I years with seasonal allergic rhiniti s and found that the drug was not associated with any sedating effects."
As is the case with their predecessors, however, secondgeneration antihistamines vary in their ability to cause adverse CN S effects. Some of the se agents hav e been consistently found to be free of sedative effects, wherea s others have been reported to be mildly sed ating in children according to objective measurements. '?Forexample, there is evidence thatcetirizine causes sedation in some children at therapeutic doses , whereas recent meta-an alys es have found that fexofenadin e is the onl y second-generation antihistamine that is consistently not associated with adv erse CNS effects.P:"
The need for objective rather than subjective ass essments of sedation in this population was highlighted by a recent rep0l1 from Ng et aJ.39They found that cetirizine 10 mg and chlorpheniramine 4 mg we re associated with significantly (p < 0.03) greater degrees of P300 latenc y (an objective EEG-based measure of somnolence) than was placebo; however, when these patients self-rated their sedation on a visual analog scale, the y reported no significant increase in sedation. De spite the difficulties of assessing the clinic al rele vance of the adverse effects of antihistamines on the CNS in children, further studies are clearly required in thi s area.
Anticholinergic effects. The poorer HI receptor specific-Volume 84, Number 3 ity of the older antihistamines has resulted in a range of anticholinergic effects caused by blockade of muscarinic receptors. Dry mouth , urinary retention , tachycardia, and constipation have all been linked to a numberoffirst-generation ag ents . In comparison, the newer H 1 antagonists have much lower affinities for musc arinic cholinergic receptors." In studies ofthe safety of fexofenadine," loratadine," and cetirizine," the incidence ofantichol inergic adverse effects was equi valent to that seen with placebo.
Cardiovascular effects . Concerns over cardiotoxicity
with first-generation and some second-generation antihistamin es have largely cent ered on poor receptor selectivity and the blockade of cardiac potassium ion channels. A number of cases of QT prolongation as a consequence of this effect were reported in patients who took astemi zole and terfenad ine. Howe ver, these agents have subsequently been withdrawn from the market in most countries ." In addition, diphenhydramine has been shown to cause a moderate but significant increase in QT c interval."
The potential for fexofenadine, loratadine, and cetiri zine to affect cardiovascul ar function has been examined, and none has been shown to have any effect on QT interval and other ECG parameters in children. In asafety study offexofenadine, 14 ch ildren with allergic rhinitis received single doses offexofenadine 30 or 60 mg." Two-lead ECG measurements were taken before and 2.5 hours after dosing, and no abnormalities were found in any ECG rhythm strip. Similar ECG findings have been observed for loratadine'" and cetirizine." These findings were supported by in vitro measurements showing that fexofenadine, loratadine , and cetiri zine have very low affinities for cardiac potassium ion channels."
Conclusion
Despite the efficacy and popularity of first-generation antihistam ines for the treatment of allergic rhinitis , these agents are associated with adve rse effects in children.Th ese effects can be avoided by using the currently available second-generation antihistamines, which have been sho wn to be not only safer, but just as effective. Given the number of second-generation preparations that are available and the differences in their specific pharm acologic attributes, care must be taken to match the particular drug to the needs of the indi vidual child.
